Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imlifidase + cyclophosphamide + glucocorticoids
- Development stage
- Unknown
- Lead developer
- Hansa Biopharma
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous (imlifidase, Cyclophosphamide), Oral (glucocorticoids, Possibly Cyclophosphamide As Per Protocol Variation)
01
Overview
This is a **combination therapy** comprising imlifidase (a recombinant IgG-degrading enzyme derived from Streptococcus pyogenes), cyclophosphamide (an alkylating agent), and glucocorticoids (synthetic corticosteroids). Imlifidase enzymatically cleaves all human IgG subclasses, providing rapid removal of pathogenic antibodies such as those in anti-GBM (Goodpasture) disease; cyclophosphamide inhibits DNA replication in proliferating lymphocytes, reducing antibody production; glucocorticoids broadly suppress immune and inflammatory responses. The combination is investigated for the treatment of severe **anti-glomerular basement membrane (anti-GBM) antibody disease** (Goodpasture Syndrome), aiming to reverse kidney failure and suppress autoantibody rebound[1][2][3][5][6].
- Other names
- Imlifidase + CYC + glucocorticoids
02
Targets
IgG lower hinge (Immunoglobulin G lower hinge region)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on imlifidase + cyclophosphamide + glucocorticoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imlifidase + cyclophosphamide + glucocorticoids.